At the physiological phenotype level, CRISPRa has also been used to increase the transcription of obesity risk genes SIM1 and MC4R, and to successfully rescue haploinsufficient obesity in mouse models—with the effects persisting up to 9 months post-treatment [80]. This evidence concerns the gene MC4R and obesity disorder.